NASDAQ:CRDL
TSX:CRDL


Cardiol Therapeutics Inc.

Address: 2265 Upper Middle Road East Suite 602 Oakville ON L6H 0G5 CA
Phone: +1 289 910-0850
Website: https://www.cardiolrx.com
Email: [email protected]

Cardiol Therapeutics Inc is a clinical-stage life sciences company developing therapies for cardiovascular disease (CVD). The lead product, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation being investigated in a Phase II/III study in hospitalized patients testing positive for COVID-19 with a prior history of, or risk factors for, CVD. The CardiolRx is also being investigated in patients with acute myocarditis, a leading cause of cardiac death in people less than 35 years old.

In The Press

Cardiol Therapeutics Inc. News

CEO Presenting on the Emerging Growth Conference on May 25 Register Now

MIAMI, May 24, 2022 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging Growth Companies and Markets announces the Schedule of the 31 st Emerging Growth Conference.

Read More

Cardiol Therapeutics Appoints Teri Loxam and Chris Waddick to its Board of Directors

Oakville, Ontario--(Newsfile Corp. - May 19, 2022) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease, is pleased to announce that its Board of Directors has appointed Teri Loxam and Chris Waddick to serve as directors, effective immediately.

Read More

Cardiol Therapeutics Announces FDA Investigational New Drug Application (IND) Authorization for Multicenter Phase II Open-Label Pilot Study of CardiolRx(TM) for Recurrent Pericarditis

Oakville, Ontario--(Newsfile Corp. - May 17, 2022) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease ("CVD"), is pleased to announce the U.S. Food and Drug Administration (FDA) has authorized the Company's Investigational New Drug Application (IND) to commence a Phase II open-label pilot study designed to evaluate the tolerance and safety of CardiolRx™, a pharmaceutically manufactured oral cannabidiol drug formulation, in patients with recurrent pericarditis. The study will also assess the improvement in objective measures of disease, and during an extension period, assess the feasibility of weaning concomitant background therapy including corticosteroids, while taking CardiolRx™. Recurrent pericarditis is an orphan disease in the United States, thereby making CardiolRx™ eligible for orphan drug status under the FDA's Orphan Drug Designation program.

Read More

Cardiol Therapeutics Announces Year-End 2021 Update on Operations

Oakville, Ontario--(Newsfile Corp. - March 24, 2022) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory therapies for the treatment of cardiovascular disease ("CVD"), today announces its year-end 2021 update on operations following the filing of its audited Financial Statements and Management's Discussion and Analysis for the year ended December 31, 2021. Both are available under the Company's profile on SEDAR at sedar.com and on the Company's website at cardiolrx.com.

Read More

Cardiol Therapeutics to Participate in Cantor Fitzgerald's Virtual Rare Orphan Disease Summit

Oakville, Ontario--(Newsfile Corp. - March 22, 2022) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory therapies for the treatment of cardiovascular disease, announced today that Cardiol's Chief Medical Officer, Dr. Andrew Hamer, will be participating in a panel discussion entitled "New World Order for Endo/CV/Renal Disease" at Cantor Fitzgerald's Virtual Rare Orphan Disease Summit on Tuesday, March 29th, at 1:00 p.m. EDT.

Read More

Cardiol Therapeutics Appoints Jennifer M. Chao to Its Board of Directors

Oakville, Ontario--(Newsfile Corp. - March 15, 2022) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory therapies for the treatment of cardiovascular disease ("CVD"), is pleased to announce that its Board of Directors has appointed Jennifer M. Chao to serve as a director, effective immediately. Ms. Chao has also been appointed Chair of the Corporate Governance and Compensation Committee.

Read More

Cardiol Therapeutics Receives Clearance from the FDA and Regulatory Agencies in Brazil and Mexico for Important Protocol Amendments Designed to Expedite Patient Enrollment in the LANCER Trial

LANCER Trial expanded to include up to 20 Additional Clinical Research Centers

Read More

Cardiol Therapeutics Appoints Thought Leaders in Cardiovascular Medicine to its Scientific Advisory Board

Oakville, Ontario--(Newsfile Corp. - January 19, 2022) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory therapies for the treatment of cardiovascular disease, today announced the appointment of Paul M. Ridker, MD, MPH, Bruce McManus, PhD, MD, and Joseph A. Hill, MD, PhD, to its Scientific Advisory Board (SAB).

Read More